Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Zura Bio ( (ZURA) ) is now available.
On February 24, 2026, Zura Bio entered into an underwriting agreement to sell 18.2 million Class A ordinary shares and 1.8 million pre-funded warrants at a public price of $6.25 per share, with the warrants priced at $6.249. The offer was conducted off an effective shelf registration and all securities were sold by the company, with holders of pre-funded warrants subject to ownership caps that limit beneficial ownership to under 10%, adjustable up to 19.99% with advance notice.
The underwriters exercised in full a 30-day option on February 25, 2026 to purchase an additional 3 million shares, bringing expected net proceeds to about $134.6 million after fees, with closing anticipated on February 26, 2026 subject to customary conditions. The transaction materially bolsters Zura Bio’s capital base as it advances its multi-asset immunology pipeline, potentially strengthening its financial position and flexibility in an increasingly competitive autoimmune and inflammatory disease drug-development landscape.
The most recent analyst rating on (ZURA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.
Spark’s Take on ZURA Stock
According to Spark, TipRanks’ AI Analyst, ZURA is a Neutral.
Score is held back primarily by weak financial performance (pre-revenue, widening losses, and significant cash burn), partially offset by strong technical momentum and positive corporate updates supporting clinical progress and a stated funding runway through 2027. Valuation signals remain constrained by unprofitability and lack of dividend data.
To see Spark’s full report on ZURA stock, click here.
More about Zura Bio
Zura Bio Limited is a clinical-stage biotechnology company focused on immunology, developing novel dual-pathway antibody therapies for autoimmune and inflammatory diseases with significant unmet medical need. Its pipeline includes lead candidate tibulizumab (ZB-106) in Phase 2 trials for hidradenitis suppurativa and systemic sclerosis, alongside early-stage assets crebankitug (ZB-168) and torudokimab (ZB-880) targeting a range of immune-mediated conditions.
Average Trading Volume: 660,905
Technical Sentiment Signal: Buy
Current Market Cap: $435M
See more insights into ZURA stock on TipRanks’ Stock Analysis page.